Foxo3 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
FOXO3 (Forkhead Box O3) is a transcription factor protein that regulates cellular stress response, longevity, DNA repair, and apoptosis. It is a member of the O subclass of the forkhead box family of transcription factors, characterized by a conserved DNA-binding domain (forkhead domain). FOXO3 is evolutionarily conserved from C. elegans (daf-16) to humans and plays critical roles in cellular homeostasis, metabolic regulation, and organismal aging.
| Property | Value |
|---|---|
| Gene | FOXO3 |
| UniProt ID | Q9Y5X3 |
| Molecular Weight | 71 kDa |
| Length | 643 amino acids |
| Subcellular Localization | Nucleus (cytoplasmic in inactive state) |
| Family | Forkhead box (Fox) family |
| PDB Structure | 2K8R, 2LCU, 4OG0 |
| Pathway | PI3K/Akt, MAPK/ERK, IKK |
The FOXO3 protein contains several functional domains:
Post-translational modifications include phosphorylation (by Akt/PKB, SGK, ERK, JNK, IKK), acetylation (by p300/CBP), and ubiquitination (by MDM2, SKP2). These modifications determine FOXO3 subcellular localization and transcriptional activity.
FOXO3 regulates a wide array of target genes involved in:
FOXO3 is one of the most robust longevity-associated genes in humans. Specific FOXO3 polymorphisms (SNPs) are associated with exceptional longevity across multiple populations. FOXO3 mediates the effects of caloric restriction on lifespan extension.
FOXO3 is widely expressed in human tissues with highest expression in:
In the brain, FOXO3 is expressed in neurons and glia, where it regulates stress response and autophagy.
FOXO3 plays a complex neuroprotective role in AD:
Therapeutic strategies targeting FOXO3 in AD include:
FOXO3 provides neuroprotection in PD models:
FOXO3 may play protective or pathogenic roles depending on context:
| Strategy | Agent/Approach | Status |
|---|---|---|
| SIRT1 activators | Resveratrol, SRT2104 | Preclinical/Phase I |
| Natural compounds | Curcumin, epigallocatechin gallate | Preclinical |
| Phosphatase activators | PP2A activators | Research |
| Gene therapy | AAV-FOXO3 | Preclinical |
The study of Foxo3 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Lin L, et al. (2010). FOXO3 in neurodegeneration: Friend or foe? J Neurosci Res. PMID:20862795
[2] Maiese K, et al. (2013). FoxO proteins: Critical regulators of oxidative stress and longevity. Adv Exp Med Biol. PMID:23627656
[3] Kalinovich M, et al. (2020). FoxO transcription factors in aging and metabolic disease. J Mol Endocrinol. PMID:32821042
[4] Kim MJ, et al. (2021). FOXO3 as a therapeutic target in neurodegenerative diseases. Front Cell Neurosci. PMID:34262452
[5] Webb AE, Brunet A. (2014). FOXO transcription factors: Key regulators of cellular quality control. Biochim Biophys Acta. PMID:24434149